Quick Answer
CONMED Corp reported Total Revenue of $1.37 billion for fiscal year 2025.
CONMED Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.37B +5.2% |
$1.31B +5.0% |
$1.24B +19.1% |
$1.05B +3.4% |
$1.01B +17.2% |
$862.46M -9.7% |
| Net Income | $47.05M -64.5% |
$132.42M +105.4% |
$64.46M +180.0% |
-$80.58M -228.8% |
$62.54M +557.2% |
$9.52M -66.7% |
| Diluted EPS | $1.51 -64.5% |
$4.25 +108.3% |
$2.04 +176.1% |
-$2.68 -238.1% |
$1.94 +506.2% |
$0.32 -67.0% |
| Total Assets | $2.33B +0.8% |
$2.31B +0.3% |
$2.30B +0.1% |
$2.30B +30.1% |
$1.77B +0.8% |
$1.75B -1.3% |
| Cash and Equivalents | — | — | — | — | — | — |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $1.03B +7.3% |
$962.68M +15.4% |
$834.22M +11.9% |
$745.54M -5.1% |
$785.43M +10.8% |
$709.04M -0.2% |
| R&D Expense | $55.88M +2.7% |
$54.43M +3.5% |
$52.60M +11.6% |
$47.15M +8.2% |
$43.56M +7.6% |
$40.47M -11.0% |
| Operating Income | $102.62M -48.8% |
$200.33M +66.1% |
$120.60M +72.2% |
$70.05M -36.2% |
$109.72M +138.5% |
$46.01M -41.8% |
| Gross Profit | $750.48M +2.4% |
$733.03M +8.4% |
$676.25M +18.4% |
$571.25M +0.6% |
$568.04M +23.4% |
$460.30M -12.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $337.93M | +6.7% | -1.3% |
| Net Income | September 30, 2025 | $2.86M | -94.2% | -86.7% |
| Diluted EPS | September 30, 2025 | $0.09 | -94.3% | -87.0% |
| Total Assets | September 30, 2025 | $2.32B | +0.3% | -0.3% |
| Cash and Equivalents | September 30, 2019 | $30.07M | +1.3% | +33.3% |
| Long-Term Debt | September 30, 2019 | $780.69M | +76.3% | -1.9% |
| Stockholders Equity | September 30, 2025 | $1.01B | +8.1% | +0.5% |
| R&D Expense | September 30, 2025 | $13.90M | +2.5% | -1.7% |
| Operating Income | September 30, 2025 | $11.88M | -81.9% | -68.9% |
| Gross Profit | September 30, 2025 | $166.12M | -7.2% | -11.8% |
- CONMED Corp reported Total Revenue of $1.37 billion for fiscal year 2025.
- CONMED Corp showed an increase of +5.2% in Total Revenue compared to the prior fiscal year.
- CONMED Corp reported Net Income of $47.05 million for fiscal year 2025.
- CONMED Corp showed a decrease of -64.5% in Net Income compared to the prior fiscal year.
- CONMED Corp reported Diluted EPS of $1.51 per share for fiscal year 2025.
- CONMED Corp showed a decrease of -64.5% in Diluted EPS compared to the prior fiscal year.
- CONMED Corp reported Total Assets of $2.33 billion for fiscal year 2025.
- CONMED Corp showed an increase of +0.8% in Total Assets compared to the prior fiscal year.
- CONMED Corp reported Cash and Equivalents of $25.86 million for fiscal year 2019.
- CONMED Corp showed an increase of +47.7% in Cash and Equivalents compared to the prior fiscal year.
- CONMED Corp reported Long-Term Debt of $438.56 million for fiscal year 2018.
- CONMED Corp showed a decrease of -7.0% in Long-Term Debt compared to the prior fiscal year.
- CONMED Corp reported Stockholders Equity of $1.03 billion for fiscal year 2025.
- CONMED Corp showed an increase of +7.3% in Stockholders Equity compared to the prior fiscal year.
- CONMED Corp reported R&D Expense of $55.88 million for fiscal year 2025.
- CONMED Corp showed an increase of +2.7% in R&D Expense compared to the prior fiscal year.
- CONMED Corp reported Operating Income of $102.62 million for fiscal year 2025.
- CONMED Corp showed a decrease of -48.8% in Operating Income compared to the prior fiscal year.
- CONMED Corp reported Gross Profit of $750.48 million for fiscal year 2025.
- CONMED Corp showed an increase of +2.4% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: